DZ2891A1 - Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number: DZ2891A1
Authority: DZ; Algeria
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; new substituted; tetrahydroquinoline derivatives
Prior art date: 1998-09-17

Application number

DZ990191A

Other languages

English (en)

French (fr)

Inventor

Michael Paul Deninno

George Tetteh

Magnus Aryitey

Roger Benjamin Ruggeri

Ronald Thure Wester

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2003-12-15

1999-09-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2891A1 publication Critical patent/DZ2891A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DZ990191A 1998-09-17 1999-09-13 Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2891A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10092798P	1998-09-17	1998-09-17

Publications (1)

Publication Number	Publication Date
DZ2891A1 true DZ2891A1 (fr)	2003-12-15

Family

ID=22282246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990191A DZ2891A1 (fr)	1998-09-17	1999-09-13	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (50)

Country	Link
US (2)	US6140343A (et)
EP (1)	EP1114032B1 (et)
JP (1)	JP3561474B2 (et)
KR (1)	KR100422286B1 (et)
CN (2)	CN1318057A (et)
AP (1)	AP1345A (et)
AR (1)	AR030523A1 (et)
AT (1)	ATE268324T1 (et)
AU (1)	AU747715B2 (et)
BG (1)	BG65101B1 (et)
BR (1)	BR9913855A (et)
CA (1)	CA2344248C (et)
CO (1)	CO5290250A1 (et)
CR (1)	CR6306A (et)
CU (1)	CU23053A3 (et)
CZ (1)	CZ2001954A3 (et)
DE (1)	DE69917790T2 (et)
DK (1)	DK1114032T3 (et)
DZ (1)	DZ2891A1 (et)
EA (1)	EA005761B1 (et)
EE (1)	EE200100167A (et)
ES (1)	ES2221420T3 (et)
GC (1)	GC0000108A (et)
GE (1)	GEP20032973B (et)
GT (1)	GT199900147A (et)
HK (1)	HK1039938A1 (et)
HR (1)	HRP20010200B1 (et)
HU (1)	HUP0103512A3 (et)
ID (1)	ID27838A (et)
IL (1)	IL141388A0 (et)
IS (1)	IS2278B (et)
MA (1)	MA26689A1 (et)
MY (1)	MY121405A (et)
NO (1)	NO319781B1 (et)
NZ (1)	NZ509837A (et)
OA (1)	OA11651A (et)
PA (1)	PA8481201A1 (et)
PE (1)	PE20001054A1 (et)
PL (1)	PL198124B1 (et)
PT (1)	PT1114032E (et)
SI (1)	SI1114032T1 (et)
SK (1)	SK3532001A3 (et)
SV (1)	SV1999000150A (et)
TN (1)	TNSN99170A1 (et)
TR (1)	TR200100780T2 (et)
TW (1)	TW502022B (et)
UA (1)	UA70960C2 (et)
WO (1)	WO2000017165A1 (et)
YU (1)	YU18101A (et)
ZA (1)	ZA200101745B (et)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US7115279B2 (en)	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) *	2001-01-26	2006-12-21	Schering Corporation	Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv) *	2001-03-30	2001-03-30	Astrazeneca Ab	New compounds
WO2002087556A2 (en) *	2001-04-11	2002-11-07	Atherogenics, Inc.	Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
KR100639745B1 (ko) *	2001-04-30	2006-10-30	화이자 프로덕츠 인크.	Ｃｅｔｐ 억제제 제조 방법
CZ20033341A3 (cs) *	2001-06-21	2004-10-13	Pfizeráproductsáinc	Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
MXPA03011784A (es) *	2001-06-22	2004-04-02	Pfizer Prod Inc	Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
CA2448825C (en)	2001-06-22	2009-08-11	Pfizer Products Inc.	Pharmaceutical compositions of adsorbates of amorphous drug
EP1269994A3 (en)	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA04005864A (es) *	2001-12-19	2004-10-29	Atherogenics Inc	Derivados de charcona y su uso para tratar enfermedades.
AU2002361811A1 (en)	2001-12-19	2003-07-09	Atherogenics, Inc.	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003055482A1 (en) *	2001-12-21	2003-07-10	Novo Nordisk A/S	Amide derivatives as gk activators
KR100664822B1 (ko) *	2002-02-01	2007-01-04	화이자 프로덕츠 인코포레이티드	변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
AR038375A1 (es)	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL371416A1 (en) *	2002-02-01	2005-06-13	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
CA2474838C (en) *	2002-02-01	2009-01-06	Pfizer Products Inc.	Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
PL215132B1 (pl) *	2002-06-27	2013-10-31	Novo Nordisk As	Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003456A (es) *	2002-10-04	2005-07-05	Millennium Pharm Inc	Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006511486A (ja) *	2002-10-21	2006-04-06	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
WO2004052863A1 (ja) *	2002-12-06	2004-06-24	Kyowa Hakko Kogyo Co., Ltd.	抗炎症剤
WO2004056727A2 (en) *	2002-12-19	2004-07-08	Atherogenics, Inc.	Process of making chalcone derivatives
ATE407670T1 (de)	2002-12-20	2008-09-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1435356A1 (en) *	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Quinoline derivatives as CRTH2 antagonists
WO2004072042A2 (en) *	2003-02-12	2004-08-26	Carex S.A.	Quinoline derivative and their use for modulation of lxr activity
AU2004222436A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CA2519432C (en)	2003-03-17	2009-06-09	Japan Tobacco Inc.	Pharmaceutical compositions comprising cetp inhibitors and a water-insoluble concentration-enhancing additive for the treatment of cardiovascular disease
US20040204450A1 (en) *	2003-03-28	2004-10-14	Pfizer Inc	Quinoline and quinoxaline compounds
EP1622872A1 (en) *	2003-03-28	2006-02-08	Pfizer Products Inc.	1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
RS20050890A (sr)	2003-05-30	2007-12-31	Ranbaxy Laboratories Limited,	Supstituisani pirol derivati
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005011635A2 (en) *	2003-08-04	2005-02-10	Pfizer Products Inc.	Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
KR20060080214A (ko)	2003-09-26	2006-07-07	니뽄 다바코 산교 가부시키가이샤	잔여 리포프로테인 생산 저해 방법
WO2005033082A2 (en) *	2003-09-30	2005-04-14	Pfizer Products Inc.	Cetp inhibitors and metabolites thereof
EP2098512A1 (en) *	2003-10-08	2009-09-09	Eli Lilly & Company	Compounds and methods for treating dyslipidemia
JP4839221B2 (ja) *	2003-11-07	2011-12-21	ジェイジェイファーマ，インコーポレイテッド	Ｈｄｌを高める併用療法用複合物
MXPA06007667A (es) *	2004-01-06	2006-09-01	Novo Nordisk As	Heteroaril-ureas y su uso como activadores de glucocinasa.
KR20060129082A (ko)	2004-03-05	2006-12-14	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20070208003A1 (en)	2004-03-26	2007-09-06	Bell Michael G	Compounds and methods for treating dyslipidemia
MY139887A (en) *	2004-04-02	2009-11-30	Mitsubishi Tanabe Pharma Corp	Tetrahydronaphthyridine derivatives and a process for preparing the same.
UA90269C2 (ru)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
WO2006009819A1 (en) *	2004-06-18	2006-01-26	Array Biopharma Inc.	Inhibitors of cholesteryl ester transfer protien
KR100859223B1 (ko) *	2004-06-24	2008-09-18	일라이 릴리 앤드 캄파니	이상지혈증 치료를 위한 화합물 및 방법
JP2008504266A (ja) *	2004-06-24	2008-02-14	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物及び方法
WO2006004903A2 (en) *	2004-06-28	2006-01-12	Atherogenics, Inc.	1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es)	2004-07-02	2011-07-15	Merck Sharp & Dohme	Inhibidores de cetp
DK1781265T3 (da) *	2004-08-25	2010-08-02	Essentialis Inc	Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
WO2006033004A1 (en) *	2004-09-23	2006-03-30	Pfizer Products Inc.	Quinoline compounds as cetp inhibitors
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
AU2005308575A1 (en) *	2004-11-23	2006-06-01	Warner-Lambert Company Llc	7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
US7700774B2 (en) *	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
CA2605214C (en)	2004-12-31	2016-07-12	Reddy Us Therapeutics, Inc.	Benzylamine derivatives as cetp inhibitors
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006082518A1 (en)	2005-02-03	2006-08-10	Pfizer Products Inc.	Pharmaceutical compositions with enhanced performance
EP1861372A1 (en)	2005-02-24	2007-12-05	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (ja) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	脂質吸収抑制方法および脂質吸収抑制剤
EP1901741B1 (en) *	2005-07-01	2015-09-16	Merck Sharp & Dohme Corp.	Process for synthesizing a cetp inhibitor
EP1904438B1 (en) *	2005-07-08	2012-02-29	Novo Nordisk A/S	Dicycloalkylcarbamoyl ureas as glucokinase activators
JP2009500377A (ja) *	2005-07-08	2009-01-08	ノボ・ノルデイスク・エー／エス	ジシクロアルキルウレア型グルコキナーゼ活性化剤
CN101263131B (zh)	2005-07-14	2013-04-24	特兰斯特克药品公司	脲葡糖激酶活化剂
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
JP4681526B2 (ja) *	2005-09-29	2011-05-11	田辺三菱製薬株式会社	医薬組成物
JP4531027B2 (ja) *	2005-09-29	2010-08-25	田辺三菱製薬株式会社	医薬組成物
KR20080059233A (ko)	2005-10-21	2008-06-26	노파르티스 아게	레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
WO2007054896A1 (en)	2005-11-08	2007-05-18	Ranbaxy Laboratories Limited	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
EP2404604B1 (en)	2006-01-05	2019-02-06	Essentialis, Inc.	Salts of potassium ATP channel openers and uses thereof
UY30118A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compueto amina trisustituido
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
TW200808731A (en)	2006-03-30	2008-02-16	Tanabe Seiyaku Co	A process for preparing tetrahydroquinoline derivatives
GB0615670D0 (en) *	2006-08-07	2006-09-13	Syngenta Participations Ag	Chemical compounds
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
CL2007002958A1 (es) *	2006-10-12	2008-05-09	Epix Delaware Inc	Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
JP2010513534A (ja) *	2006-12-21	2010-04-30	エージェリオンファーマシューティカルズ，インコーポレイテッド	Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
WO2008084043A1 (en) *	2007-01-09	2008-07-17	Novo Nordisk A/S	Urea glucokinase activators
JP5226008B2 (ja)	2007-01-11	2013-07-03	ノボ・ノルデイスク・エー／エス	ウレアグルコキナーゼアクチベーター
CN101220021B (zh) *	2007-01-12	2010-12-08	上海医药工业研究院	4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
NZ580777A (en)	2007-04-13	2011-05-27	Kowa Co	Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
CN101795691A (zh) *	2007-07-02	2010-08-04	伊森舍丽斯有限公司	钾atp通道开放剂的盐及其用途
AR069165A1 (es)	2007-11-05	2010-01-06	Novartis Ag	Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
ES2425776T3 (es)	2007-12-03	2013-10-17	Novartis Ag	Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis
EP2280766A1 (en)	2007-12-11	2011-02-09	CytoPathfinder, Inc.	Carboxamide compounds and their use as chemokine receptor agonists
BRPI1012852A2 (pt)	2009-05-15	2018-06-19	Novartis Ag	derivados de benzoxazolona como inibidores da sintase de aldoesterona
ES2459468T3 (es)	2009-05-15	2014-05-09	Novartis Ag	Arilpiridinas como inhibidores de aldosterona sintasa
EP3048100A1 (en)	2009-05-28	2016-07-27	Novartis AG	Substituted aminobutyric derivatives as neprilysin inhibitors
ES2523734T3 (es)	2009-05-28	2014-12-01	Novartis Ag	Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
TWI450896B (zh)	2009-06-30	2014-09-01	Lilly Co Eli	反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
WO2011061168A1 (en)	2009-11-17	2011-05-26	Novartis Ag	Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja)	2009-11-30	2014-08-20	ノバルティスアーゲー	アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
WO2011145022A1 (en)	2010-05-21	2011-11-24	Pfizer Inc.	2-phenyl benzoylamides
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP2668507B1 (en)	2011-01-26	2017-08-23	INSERM - Institut National de la Santé et de la Recherche Médicale	Method for assessing a subject's risk of having a cardiovascular disease.
US20130345392A1 (en)	2011-03-04	2013-12-26	Pfizer Inc	Edn3-like peptides and uses thereof
BR112013032557A2 (pt)	2011-06-17	2020-09-24	Merck Sharp & Dohe Corp.	composto, formulação farmacêutica, uso de um composto, e, uso de um composto e um agente terap~eutico adicional
TWI537262B (zh) *	2011-08-17	2016-06-11	美國禮來大藥廠	供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
JP5964965B2 (ja)	2011-08-18	2016-08-03	ドクターレディズラボラトリーズリミテッド	コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
KR101803866B1 (ko)	2011-09-27	2017-12-04	닥터 레디스 레보러터리즈 리미티드	동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
MX347400B (es)	2012-06-29	2017-04-18	Univ Nac Autónoma De México	Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105073762B (zh)	2013-02-14	2017-03-08	诺华股份有限公司	作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
MX2015014666A (es)	2013-04-17	2016-03-01	Pfizer	Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
AU2014293386B2 (en)	2013-07-25	2016-11-17	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
MX2016001021A (es)	2013-07-25	2016-08-03	Novartis Ag	Bioconjugados de polipeptidos de apelina sinteticos.
EP3185869A1 (en) *	2014-08-28	2017-07-05	Dezima Pharma B.V.	PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS
CA2959208C (en)	2014-08-29	2023-09-19	Tes Pharma S.R.L.	Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
PE20171328A1 (es)	2015-01-23	2017-09-12	Novartis Ag	Conjugados de acidos grasos y apelina sintetica con mayor vida media
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
MX2020008905A (es)	2018-06-12	2020-12-03	Vtv Therapeutics Llc	Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
US11248001B2 (en)	2019-01-18	2022-02-15	Astrazeneca Ab	PCSK9 inhibitors and methods of use thereof
US12391658B2 (en)	2020-02-18	2025-08-19	Vtv Therapeutics Llc	Sulfoxide and sulfone glucokinase activators and methods of use thereof
WO2021252311A1 (en)	2020-06-08	2021-12-16	Vtv Therapeutics Llc	Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
CA3186856A1 (en)	2020-07-29	2022-02-03	Ruth NALLEN	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CN121219288A (zh)	2023-05-24	2025-12-26	诺华股份有限公司	用于治疗疾病或障碍的萘啶酮衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231102A (en) *	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) *	1990-06-18	1994-01-04	E. R. Squibb & Sons, Inc.	Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en)	1990-11-26	1995-03-28	E. R. Squibb & Sons, Inc.	Indane and quinoline derivatives
JPH0676403B2 (ja) *	1991-01-18	1994-09-28	エスエス製薬株式会社	新規なベンゾ［５，６シクロヘプタ［１，２−ｂピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) *	1992-10-15	1994-02-22	Merck & Co., Inc.	Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) *	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en)	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6462091B1 (en)	1998-12-23	2002-10-08	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

1999
- 1999-09-06 GT GT199900147A patent/GT199900147A/es unknown
- 1999-09-07 US US09/391,313 patent/US6140343A/en not_active Expired - Fee Related
- 1999-09-08 GC GCP1999273 patent/GC0000108A/xx active
- 1999-09-08 PA PA19998481201A patent/PA8481201A1/es unknown
- 1999-09-10 SK SK353-2001A patent/SK3532001A3/sk unknown
- 1999-09-10 AT AT99940426T patent/ATE268324T1/de not_active IP Right Cessation
- 1999-09-10 YU YU18101A patent/YU18101A/sh unknown
- 1999-09-10 HR HR20010200A patent/HRP20010200B1/xx not_active IP Right Cessation
- 1999-09-10 SI SI9930595T patent/SI1114032T1/xx unknown
- 1999-09-10 BR BR9913855-7A patent/BR9913855A/pt not_active Application Discontinuation
- 1999-09-10 IL IL14138899A patent/IL141388A0/xx not_active IP Right Cessation
- 1999-09-10 ID IDW20010621A patent/ID27838A/id unknown
- 1999-09-10 MY MYPI99003926A patent/MY121405A/en unknown
- 1999-09-10 DK DK99940426T patent/DK1114032T3/da active
- 1999-09-10 CN CN99811014A patent/CN1318057A/zh active Pending
- 1999-09-10 GE GEAP19995804A patent/GEP20032973B/en unknown
- 1999-09-10 AR ARP990104554A patent/AR030523A1/es active IP Right Grant
- 1999-09-10 AU AU54403/99A patent/AU747715B2/en not_active Ceased
- 1999-09-10 ES ES99940426T patent/ES2221420T3/es not_active Expired - Lifetime
- 1999-09-10 CN CNA2004100049599A patent/CN1515259A/zh active Pending
- 1999-09-10 OA OA1200100062A patent/OA11651A/en unknown
- 1999-09-10 EP EP99940426A patent/EP1114032B1/en not_active Expired - Lifetime
- 1999-09-10 UA UA2001031791A patent/UA70960C2/uk unknown
- 1999-09-10 CA CA002344248A patent/CA2344248C/en not_active Expired - Fee Related
- 1999-09-10 WO PCT/IB1999/001534 patent/WO2000017165A1/en not_active Ceased
- 1999-09-10 SV SV1999000150A patent/SV1999000150A/es not_active Application Discontinuation
- 1999-09-10 EA EA200100249A patent/EA005761B1/ru not_active IP Right Cessation
- 1999-09-10 DE DE69917790T patent/DE69917790T2/de not_active Expired - Fee Related
- 1999-09-10 HK HK02101447.5A patent/HK1039938A1/zh unknown
- 1999-09-10 AP APAP/P/2001/002100A patent/AP1345A/en active
- 1999-09-10 CO CO99057641A patent/CO5290250A1/es not_active Application Discontinuation
- 1999-09-10 EE EEP200100167A patent/EE200100167A/et unknown
- 1999-09-10 CU CU20010051A patent/CU23053A3/es unknown
- 1999-09-10 PL PL346830A patent/PL198124B1/pl not_active IP Right Cessation
- 1999-09-10 HU HU0103512A patent/HUP0103512A3/hu unknown
- 1999-09-10 KR KR10-2001-7003416A patent/KR100422286B1/ko not_active Expired - Fee Related
- 1999-09-10 PT PT99940426T patent/PT1114032E/pt unknown
- 1999-09-10 TR TR2001/00780T patent/TR200100780T2/xx unknown
- 1999-09-10 JP JP2000574075A patent/JP3561474B2/ja not_active Expired - Fee Related
- 1999-09-10 CZ CZ2001954A patent/CZ2001954A3/cs unknown
- 1999-09-10 NZ NZ509837A patent/NZ509837A/xx unknown
- 1999-09-10 TW TW088115688A patent/TW502022B/zh not_active IP Right Cessation
- 1999-09-10 PE PE1999000922A patent/PE20001054A1/es not_active Application Discontinuation
- 1999-09-13 MA MA25766A patent/MA26689A1/fr unknown
- 1999-09-13 DZ DZ990191A patent/DZ2891A1/xx active
- 1999-09-13 TN TNTNSN99170A patent/TNSN99170A1/fr unknown
2000
- 2000-09-27 US US09/671,221 patent/US6489478B1/en not_active Expired - Fee Related
2001
- 2001-02-14 CR CR6306A patent/CR6306A/es unknown
- 2001-02-23 IS IS5858A patent/IS2278B/is unknown
- 2001-03-01 ZA ZA200101745A patent/ZA200101745B/en unknown
- 2001-03-16 NO NO20011349A patent/NO319781B1/no not_active IP Right Cessation
- 2001-04-10 BG BG105429A patent/BG65101B1/bg unknown

Also Published As

Publication number	Publication date
HUP0103512A2 (hu)	2002-02-28
EE200100167A (et)	2002-06-17
CN1318057A (zh)	2001-10-17
ATE268324T1 (de)	2004-06-15
JP3561474B2 (ja)	2004-09-02
CZ2001954A3 (cs)	2001-12-12
NO20011349D0 (no)	2001-03-16
AP1345A (en)	2004-12-15
US6489478B1 (en)	2002-12-03
EP1114032B1 (en)	2004-06-02
ID27838A (id)	2001-04-26
TR200100780T2 (tr)	2001-07-23
CU23053A3 (es)	2005-06-24
BR9913855A (pt)	2001-07-24
GC0000108A (en)	2005-06-29
IS5858A (is)	2001-02-23
EA200100249A1 (ru)	2001-08-27
DK1114032T3 (da)	2004-08-16
IL141388A0 (en)	2002-03-10
HK1039938A1 (zh)	2002-05-17
CA2344248A1 (en)	2000-03-30
CO5290250A1 (es)	2003-06-27
DE69917790D1 (de)	2004-07-08
NZ509837A (en)	2002-11-26
GEP20032973B (en)	2003-05-27
OA11651A (en)	2004-12-07
BG65101B1 (bg)	2007-02-28
ZA200101745B (en)	2002-05-02
HUP0103512A3 (en)	2002-03-28
IS2278B (is)	2007-09-15
PT1114032E (pt)	2004-09-30
UA70960C2 (uk)	2004-11-15
NO20011349L (no)	2001-05-14
YU18101A (sh)	2004-05-12
AU747715B2 (en)	2002-05-23
HRP20010200B1 (en)	2006-10-31
CA2344248C (en)	2007-01-09
NO319781B1 (no)	2005-09-12
MY121405A (en)	2006-01-28
CR6306A (es)	2003-08-28
WO2000017165A1 (en)	2000-03-30
SK3532001A3 (en)	2001-12-03
TNSN99170A1 (fr)	2005-11-10
JP2002526476A (ja)	2002-08-20
EA005761B1 (ru)	2005-06-30
US6140343A (en)	2000-10-31
TW502022B (en)	2002-09-11
AR030523A1 (es)	2003-08-27
ES2221420T3 (es)	2004-12-16
SV1999000150A (es)	2000-06-06
DE69917790T2 (de)	2005-06-09
SI1114032T1 (et)	2004-12-31
AU5440399A (en)	2000-04-10
AP2001002100A0 (en)	2001-03-31
HRP20010200A2 (en)	2002-04-30
PE20001054A1 (es)	2000-10-14
GT199900147A (es)	1999-09-06
KR20010085814A (ko)	2001-09-07
MA26689A1 (fr)	2004-12-20
BG105429A (en)	2001-12-29
PL346830A1 (en)	2002-02-25
CN1515259A (zh)	2004-07-28
PL198124B1 (pl)	2008-05-30
PA8481201A1 (es)	2000-09-29
EP1114032A1 (en)	2001-07-11
KR100422286B1 (ko)	2004-03-11

Publication	Publication Date	Title
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr)	2002-12-25	Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2880A1 (fr)	2003-12-15	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2457A1 (fr)	2004-11-08	Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.